Moleculin Biotech Company Insiders
| MBRX Stock | USD 2.62 0.03 1.13% |
Moleculin Biotech's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Moleculin Biotech suggests that vertually all insiders are extremely bullish. Moleculin Biotech employs about 18 people. The company is managed by 10 executives with a total tenure of roughly 42 years, averaging almost 4.0 years of service per executive, having 1.8 employees per reported executive.
Moleculin Biotech's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-12-26 | Walter V Klemp | Acquired 12560 @ 10.35 | View |
Monitoring Moleculin Biotech's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Moleculin |
Moleculin Biotech's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Moleculin Biotech's future performance. Based on our forecasts, it is anticipated that Moleculin will maintain a workforce of slightly above 18 employees by December 2024.Moleculin Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.5745) % which means that it has lost $0.5745 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4149) %, meaning that it created substantial loss on money invested by shareholders. Moleculin Biotech's management efficiency ratios could be used to measure how well Moleculin Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.15 in 2024. Return On Capital Employed is likely to drop to -0.99 in 2024. At this time, Moleculin Biotech's Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 3.3 M in 2024, whereas Total Assets are likely to drop slightly above 35.4 M in 2024.Common Stock Shares Outstanding is likely to drop to about 1.6 M in 2024. Net Loss is likely to drop to about (15 M) in 2024
Moleculin Biotech Workforce Comparison
Moleculin Biotech is regarded fifth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 472. Moleculin Biotech holds roughly 18.0 in number of employees claiming about 4% of equities under Health Care industry.
Moleculin Biotech Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moleculin Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moleculin Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Moleculin Biotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 0.5 | 1 | 2 | 982.00 | 1,222 |
| 2024-06-01 | 0.6 | 9 | 15 | 25,650 | 30,841 |
| 2023-09-01 | 0.5 | 2 | 4 | 27,921 | 34,721 |
| 2023-06-01 | 1.6 | 16 | 10 | 1,780,585 | 187,356 |
| 2022-09-01 | 0.25 | 2 | 8 | 27,921 | 69,442 |
| 2022-06-01 | 5.5 | 22 | 4 | 2,413,499 | 46,632 |
| 2021-09-01 | 0.5 | 2 | 4 | 27,923 | 34,722 |
| 2020-09-01 | 3.0 | 6 | 2 | 1,592,438 | 98,519 |
| 2017-09-01 | 1.5 | 3 | 2 | 50,000 | 200,000 |
| 2009-03-01 | 0.2222 | 2 | 9 | 240,886 | 230,136 |
| 2008-06-01 | 2.2778 | 41 | 18 | 5,638,661 | 1,296,917 |
| 2007-06-01 | 1.5 | 3 | 2 | 30,000 | 4,300 |
| 2007-03-01 | 1.0 | 1 | 1 | 60,000 | 700.00 |
| 2006-06-01 | 3.5 | 7 | 2 | 80,000 | 500.00 |
| 2005-09-01 | 6.0 | 12 | 2 | 2,102,389 | 1,399,318 |
| 2004-06-01 | 1.1818 | 26 | 22 | 15,290,300 | 61,269,531 |
Moleculin Biotech Notable Stakeholders
A Moleculin Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moleculin Biotech often face trade-offs trying to please all of them. Moleculin Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moleculin Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Walter Klemp | Chairman, CoFounder | Profile | |
| Jonathan CPA | Executive CFO | Profile | |
| Louis Ploth | Independent Advisor | Profile | |
| ScD MD | Senior Officer | Profile | |
| Jacqueline Northcut | Consultant | Profile | |
| Donald Picker | Chief Officer | Profile | |
| Waldemar Priebe | Founding CoFounder | Profile | |
| FACP MD | Chief Annamycin | Profile | |
| MD FACP | Chief Annamycin | Profile | |
| MBA MD | European Officer | Profile |
About Moleculin Biotech Management Performance
The success or failure of an entity such as Moleculin Biotech often depends on how effective the management is. Moleculin Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moleculin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moleculin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.10) | (1.15) | |
| Return On Capital Employed | (0.94) | (0.99) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (1.14) | (1.08) |
Please note, the imprecision that can be found in Moleculin Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moleculin Biotech. Check Moleculin Biotech's Beneish M Score to see the likelihood of Moleculin Biotech's management manipulating its earnings.
Moleculin Biotech Workforce Analysis
Traditionally, organizations such as Moleculin Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moleculin Biotech within its industry.Moleculin Biotech Manpower Efficiency
Return on Moleculin Biotech Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 3M | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 1.9M |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.